Introduction
Activin A is a member of the activin/inhibin family of dimeric polypeptides belonging to the transforming growth factor (TGF) b superfamily. Like the prototypic molecule, activin A is a pleiotropic cytokine exhibiting a variety of functions depending on the target cell and on environmental cues (Reviewed by Mathews, 1994) . In addition to its multiple functions in dierentiation and morphogenesis, activin A controls cell growth in various systems. It stimulates DNA synthesis (Miro and Hillier, 1996) and suppresses apoptosis in granulosa cells (Chun et al., 1996) and, by contrast, it is involved in processes of negative growth regulation in other cell types; activin A was shown to kill plasma-like cells by an apoptotic process (Nishihara et al., 1993; Sternberg et al., 1995; Koseki et al., 1995) , by antagonizing the growth stimulating eect of interleukin (IL)-6 , and to arrest human breast cells in the G1 phase of the cell cycle (Liu et al., 1996a) . Similarly, it inhibits epidermal growth factor induced initiation of DNA synthesis in rat hepatocytes (Yasuda et al., 1993) and prolongation of G1 phase in K562 erythroleukemic cells (Sehy et al., 1992) .
The sequence of events along the activin A signaling pathway is only partially known. Activin receptors type II (ActRII) and ActRIIB are ligand binding proteins whereas an additional type of receptor, activin receptor type I (ActRI), associates with the former but is incapable of directly binding activin A (reviewed in Mathews, 1994) . Upon ligand binding, ActRIIB phosphorylates ActRIB which in turn acts as a downstream signal transducer . Indeed, a mutated actRIB was found to constitutively transduce in the absence of ligand. Further downstream events in the signaling cascade of activin A in mammalian cells are largely unknown. Activin A induces changes in calcium concentration (Mine et al., 1989) and activation of a pertussis toxin-sensitive G protein (Kaipia et al., 1993; Bhasin et al., 1989) in hepatocytes. It was further found, using the yeast twohybrid system, that the p21 ras farnesyltransferase (FNTA) a subunit, is bound to the TGFb and activin type I receptors, and is phosphorylated and released intracellularly upon ligand binding (Wang et al., 1996) . A common response to activin A signaling is transcriptional activation of the early response gene junB (Hashimoto et al., 1993; Brosh et al., 1995) . p21 ras (Whitman and Melton, 1992; Mulder and Morris, 1992) and other components of the MEK, MAPK cascades as well as G proteins (Murthy et al., 1988) have been implicated in a variety of cell systems as targets of TGFb family members. Whether any of these events are obligatory steps in activin A mediated growth inhibition is not known.
Growth inhibition can often be mediated by reduced phosphorylation of the product of the retinoblastoma susceptibility gene (Rb) (reviewed by Weinberg, 1995; Whyte, 1995; Beijersbergen and Bernards, 1996) . Hypo-phosphorylated Rb binds to, and negatively regulates the activities of transcription factors of the E2F family, whose function is important for the G1/S transition (reviewed by La Thangue, 1994) . Phosphorylation and inactivation of Rb in G1 is mediated by cyclin dependent kinase-4 (CDK4) associated with cyclin D (Resnitzky and Reed, 1995) and possibly also by CDK2 associated with cyclin E (reviewed by Weinberg, 1995) . The activity of these CDKs, which are components of the cell cycle regulatory machinery (reviewed by Nigg, 1995) , can be inhibited by a family of CDK inhibitors (CKIs) (reviewed by Sherr and Roberts, 1995) . In the present study we show that activin A-mediated growth suppression involves CDK4 and Rb and further includes p53 dependent transcriptional activation of the p21 WAF1/Cip1 gene promoter.
Results
Activin A has been shown to inhibit the growth of primary hepatocytes (Yasuda et al., 1993; Mitaka et al., 1995) . Here, we examined the response of human HepG2 hepatoma cells to this cytokine, with the aim of analysing activin A-induced signaling pathways. Time dependent follow up of HepG2 hepatoma cell growth was performed using a colorimetric viability assay. Figure 1a shows that cultures of HepG2 hepatoma cells seeded in the presence of activin A, did not exhibit any net increase in cell number throughout a 5 day period, as compared to a threefold increase in the control cultures. Activin A treated cells incorporated sixfold less [
3 H]thymidine after 48 h (Figure 1b ) while at the same time the cell number was inhibited by only one third ( Figure 1a) . It is therefore concluded that activin A inhibits DNA synthesis and arrests growth of HepG2 hepatoma cells. This ®nding is not restricted to the HepG2 cell line, since similar growth inhibition of Huh-7 hepatoma cells was also found (results not shown). No signs of cell death by apoptosis or lysis could be observed by microscopic examination or bȳ ow cytometry. To elucidate the mechanism underlying this activin A-mediated growth arrest, we ®rst examined the phosphorylation state of pRb. As shown in Figure 2 , the hyperphosphorylated form is predominant in growing cells. Following 9 h of incubation with activin A the faster migrating, underphosphorylated form of Rb, started to accumulate in the cells, becoming even more abundant after 24 h. This suggests that the growth inhibitory eect of activin A is mediated at least in part, via inhibition of pRb phosphorylation. Changes in pRb phosphorylation can be due to alteration in Rb kinases and/or their inhibitors. We therefore measured the levels of CDK4 and p21 WAF1/Cip1 using Western blot analysis. As shown in Figure 3 , CDK4 levels decreased threefold following 9 h incubation of HepG2 cells with activin A; no further decrease was observed at 24 h. In contrast, the level of p21 WAF1/Cip1 increased following activin A treatment ( Figure 4 ). Elevated amounts of p21
were detected already at 3 h post exposure to activin A. The relative amount of p21 WAF1/Cip1 further increased as a function of time, and was, at 24 h, 16-fold higher in , at 3 h post induction, occurred also in activin A treated plasmacytoma cells (not shown) in which activin A causes a shift to the G0/G1 phase of the cell cycle and subsequent apoptotic cell death .
To study the expression of p21 WAF1/Cip1 at the mRNA level RT ± PCR, using primers for human p21 transcription is known to be activated by the tumor supressor protein, p53 (El Deiry et al., 1993) . HepG2 cells contain endogenous wild type p53 (Puisieux et al., 1993) . To evaluate the possible contribution of p53 to the activin A-induced activation of p21 WAF1/Cip1 transcription, we took advantage of a miniprotein containing the C-terminal portion of p53 (amino acids 315 ± 390). This miniprotein has been shown to exert a dominant negative eect on the functions of wild type p53 (Shaulian et al., 1992) . The pCMVN315 plasmid, encoding this miniprotein, was transfected into HepG2 cells together with a luciferase reporter driven by the p21 WAF1/Cip1 promoter. As shown in Figure 6 , pCMVN315 reduced basal promoter activity and totally blocked the increased transcription from the p21 WAF1/Cip1 promoter, observed upon activin A induction. This suggests that the endogenous wild type p53 of HepG2 cells is required for the eect of activin A on p21 WAF1/Cip1 . p21 WAF1/Cip1 transcription was also reported to be activated by STAT transcription factors (Chin et al., 1996) . We therefore tested the eect of activin A on transcriptional activation through STAT sites. Figure  7a and b demonstrate that, in HepG2 cells, activin A WAF1/Cip1 and for actin, as control, with a limited number of cycles, on RNA extracted from HepG2 cells, before and after 9 and 24 h treatment with 300 units/ml activin A. HepG2 cells were further transiently transfected with a plasmid containing the p21 WAF1/Cip1 promoter upstream to a luciferase reporter gene. Identical cultures were transfected with the plasmid at the same time and treated with 300 units/ml activin A for 3, 9, 24, 48 and 56 h before the end of culture. The cultures were all harvested at the same time and luciferase activity determined. A control transfected culture to which no activin A was added (7) was harvested together with the activin A treated cultures and luciferase activity determined promoter by activin A. HepG2 cells were transfected with a luciferase reporter plasmid containing the p21 WAF1/Cip1 promoter, with or without the addition of pCMVN315, encoding the Cterminal domain of p53. Following overnight incubation, the indicated cultures were exposed to 300 units/ml activin A. Extracts were prepared 65 h later and assayed for luciferase activity p21 WAF1/Cip1 , CDK4 and Rb in activin A signaling A Zauberman et al did not aect transcription from two dierent STAT sites, one derived from the IRF-1 gene promoter (pIRE/IRF-1), and the other from the a2M gene promoter (pIRE/a2M, Harroch et al., 1994) . In contrast and as expected, interleukin (IL)-6 caused a dramatic transcriptional activation of the same promoter.
Discussion
This study demonstrates that hepatoma cells, like their normal counterparts, primary hepatocytes, are sensitive to the growth inhibitory eect of activin A. At 90 ng/ ml (300 U/ml) activin A caused complete growth inhibition of HepG2 hepatoma cells. Analysis of components of the cell cycle control machinery showed that the expression of the CKI p21 WAF1/Cip1 (El Deiry et al., 1993; Gu et al., 1993; Harper et al., 1993; Noda et al., 1994; Xiong et al., 1993) is increased, while that of the cyclin dependent kinase CDK4 is diminished. An additional regulatory protein, MDM2 (Momand et al., 1992; Barak et al., 1993) , was unaected following treatment with activin A (results not shown). The possible involvement of p53 in the stimulation of p21 WAF1/Cip1 transcription was examined by negative dominant inactivation of endogenous p53. The miniprotein encoded by the plasmid pCMVN315 oligomerizes with full length wild type p53, abrogates sequence-speci®c DNA binding and suppresses p53 functions (Shaulian et al., 1992 probably causes reduced CDK4 activity. However, as shown here, CDK4 protein itself is also found in reduced amount following addition of activin A. This may be mediated through a mechanism independent of p21 WAF1/Cip1 (Figure 8) .
In dierent systems, pRb hypophosphorylation occurs as a result of distinct signaling cascades (reviewed by Massague and Polyak, 1995 , inhibit CDK4 activity and cause G1 arrest (Reynisdottir et al., 1995) . A completely dierent mechanism was reported to be responsible for the G1 arrest that accompanies induction of dierentiation in erythroleukemia cells. In this case, the dierentiation inducer causes a rapid decrease in the level of CDK4, due to decrease in protein stability (Kiyokawa et al., 1994) . As shown here, HepG2 cell growth inhibition involves both a decrease in CDK4 and a p53 dependent activation of p21 WAF1/Cip1 transcription. By contrast, in HaCaT cells TGFb activates transcription of p21 independently of p53 (Reynisdottir et al., 1995) .
The p21 WAF1/Cip1 promoter has also been found to be regulated by the jak/STAT pathway. Chin et al. (1996) showed that the epidermoid carcinoma cell line A431 is growth inhibited by epidermal growth factor (EGF) and that in these cells STAT1 and STAT3 are activated. In fact, STAT activation was found to Upstream to a luciferase reporter gene. 24 h later cells were treated for 12 h with 300 units/ ml activin A, or 100 units/ml IL-6 and luciferase activity was determined relative to control untreated cells (7) Figure 8 A schematic model interpreting the results presented in this study. It is demonstrated that the reduced activity of CDK4 leading to growth inhibition is partially due to reduction in CDK4 protein expression through an activin A induced pathway that does not involve p21 WAF1/Cip1 (WAF1). In addition, activin A acts through p53 dependent and independent pathways to increase p21 WAF1/Cip1 expression and reduce CDK4 activity . We found that in the HepG2 hepatoma cells, activin A did not aect transcription from two distinct STAT binding sites. STAT proteins may therefore not be involved in mediating the activin A growth inhibitory signal in this system. Activin A was ®rst studied as an inducer of follicle stimulating hormone (FSH) release (Vale et al., 1986; Ling et al., 1986) , and was later found to be a pleiotropic cytokine exhibiting a variety of dierent functions (Murata et al., 1988; Fujimoto et al., 1991; Asashima et al., 1990; Smith et al., 1990; van den Eijnder et al., 1990; Thomsen et al., 1990; Matzuk et al., 1995; Zipori et al., 1986; Brosh et al., 1995) . Included among its biological functions are also induction of growth inhibition and cell death. We describe here aspects of the signaling pathway by which activin A inhibits hepatoma cell growth. This pathway diers from the one through which plasmacytomas and hybridomas are killed by activin A, which is related to the growth dependence of these cells on IL-6. Thus activin A is a competitive inhibitor of IL-6 signaling, deprives plasmalike cells of their growth stimulus and mediates growth arrest and apoptosis .
TGFb is a potent growth inhibitor in most biological systems studied (Reviewed by Polyak, 1996) . Activin A has a dierent target cell range for growth inhibition. Therefore, cell type speci®c signaling pathways may be involved in activin A-mediated growth inhibition. The identi®cation of Mad proteins involved in TGFb signaling indeed indicates that the dierent, cytokine speci®c, outcome of signaling, is dependent on the existence of distinct eector protein species (Gra et al., 1996; Liu et al., 1996b; Hoodless et al., 1996) .
Materials and methods

Cell lines and cell culture
HepG2, human hepatoma cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% FCS (Beth Haemek, Israel), 20 mM Lglutamine, 100 units/ml penicillin and 100 mg/ml streptomycin.
Cytokines
Restrictin-P (activin A of bone marrow stroma origin) was puri®ed to homogeneity in our laboratory from serum free media conditioned by the stromal cell clone MBA-2.1 as previously reported . One unit of activin A was determined using the biological assay of plasmacytoma cell growth inhibition (Zipori et al., 1986; and is equal to 300 pg.
Antibodies
Monoclonal antibodies (Pharmingen, San Diego, CA) to retinoblastoma and to p21 WAF1/Cip1 were both used at a dilution of 1 : 500. Polyclonal antiserum to CDK4 (C-22) (Santa Cruz Biotechnology, CA) were used at 1 : 1000. Monoclonal anti alpha-tubulin, ascetic¯uid (Sigma, Israel) was diluted 1 : 5000.
Cell viability assay
The bioassay was performed as previously described (Kadouri et al., 1992) . Brie¯y, cells were seeded at 3610 4 /ml in 96-well microtiter plates (Falcon), in 100 ml of DMEM containing 8% FCS with highly puri®ed murine activin A or Tris buer (negative control). Cells were incubated for 4 days at 378C and their viability was estimated by the MTT 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay (Mosmann, 1983) , which measures cell viability via mitochondrial activity. Absorbance was determined at a wave length of 570 nm with background substraction at 630 nm. 
Protein extraction
Cell extracts were prepared in 1 ml of extraction buer (1% Triton X-100, 25 mM Tris HCl pH 7.5, 250 mM, NaCl, 2 mM EDTA) supplemented with 10 mg/ml aprotinin and 1 mM PMSF. Samples were vigorously mixed by vortex and then incubated on ice for 15 min and remixed as above every 5 min. Samples were then centrifuged at 14 000 g for 10 min at 48C and protein concentration was determined by Bradford assay in each extract and an equal amount of protein was loaded per lane.
Western blotting
Extracts were subjected to SDS ± PAGE and transferred onto nitrocellulose membranes (Sambrook et al., 1989) . The blots were washed twice for 20 min with blocking solution (10% low-fat milk, 0.05% Tween 20 in PBS). Hybridoma supernatants or polyclonal antibody were added, followed by goat anti-mouse horseradish peroxidase-conjugated antibodies or horseradish peroxidase protein A, respectively. Chemiluminescent signals were generated by incubation with the ECL reagent according to the manufacturer's instructions. The gel was exposed to X-ray ®lm.
Reverse transcriptase -polymerase chain reaction (RT ± PCR) cDNA synthesis 8 mg of total cellular RNA extracted with TRI REAGENT (MRC, Cincinnati, OH) was resuspended in a reaction volume of 20 ml containing dNTPs (0.5 mM each), 0.5 mg of oligo(dT) primer (Promega), MMLV-RT 16buer (Promega), 5 mM DTT and 200 units of MMLVreverse transcriptase (Promega) and incubated for 1 h at 378C.
PCR reaction 20 cycles of the PCR reactions were carried out in a thermal cycler (Techne, Cambridge, UK). Each cycle consisted of the following steps: 958C for 30 s, 588C for 30 s and 728C for 1 min, using primers for the human p21 WAF1/Cip1 and actin genes. The PCR products were separated on a 1.8% agarose gel. 
Luciferase assay
Transient transfections with the appropriate vectors were carried out using the calcium phosphate method as previously described (Graham and Eb, 1973) . For luciferase assays cells were plated in six well plates (Falcon) and transfected with 0.5 mg of the reporter plasmid and a total of 2 mg of pCMVN315 DNA or vector alone in a ®nal volume of 1.5 ml. Six hours after transfection the cells underwent glycerol shock and were then incubated in the presence or absence of 300 u/ml activin A. After 65 h cells were harvested and luciferase activity in cell lysates was determined according to standard procedure with the aid of a Turner Designs luminometer.
